Travere Therapeutics (TVTX) announced that the FDA has informed the company that following further review of the supplemental new drug application for Filspari in focal segmental glomerulosclerosis, an advisory committee is no longer needed. The sNDA remains under review by the FDA with a Prescription Drug User Fee Act target action date of January 13, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Optimistic Outlook for Travere Therapeutics Driven by Regulatory Advancements and Market Opportunities
- Nvidia reports Q2 beat, Snowflake posts ‘beat and raise’: Morning Buzz
- Ligand price target raised to $206 from $157 at H.C. Wainwright
- Travere Therapeutics price target raised to $47 from $30 at H.C. Wainwright
- Buy Rating Affirmed for Travere Therapeutics Amid Positive FDA Changes for Filspari